Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial
Authors
Parry, M.Grist, E.
Brawley, C.
Proudfoot, J. A.
Mendes, L.
Lall, S.
Hoyle, Alex P
Sachdeva, Ashwin
Liu, Y.
Amos, C.
Sydes, M. R.
Jones, R.
Parmar, M. K.
Feng, F.
Sweeney, C. J.
Clarke, Noel W
Davicioni, E.
James, N. D.
Brown, L.
Attard, G.
Affiliation
Oncology Department - Treatment Resistance, UCL Cancer Institute - Paul O’Gorman Building, London, UKIssue Date
2022
Metadata
Show full item recordCitation
Parry M, Grist E, Brawley C, Proudfoot JA, Mendes L, Lall S, et al. Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial. Annals of Oncology. 2022 Sep;33(7):S1161-S. PubMed PMID: WOS:000866211601615.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.07.1491Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.07.1491Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.07.1491